MAPT and Alzheimer disease: As previously reported, CJD patients present with a significant increase in the t-tau/p-tau ratio (97.5, IQR 42.6–185.7; n = 294) in comparison to both AD (7.9, IQR 6.7–10.2; n = 85) and other non-CJD (15.2, IQR 8.0–31.2; n = 226) subjects (CJD vs. AD p < 0.001; CJD vs. non-CJD p < 0.001; AD vs. non-CJD p < 0.001).